Gene Editing In China: EdiGene Raises Fresh Funds, Aims For First IND
'Great Leap' From Gene-Edited Babies to One-Time Cures
With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.
You may also be interested in...
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.
From requiring early notification to whole-process involvement, China is clearing a path for a far-reaching new biosecurity law, which if implemented will pose high hurdles for international firms planning to conduct clinical studies in the country, industry observers say.
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.